|
[1]
|
Tak, Y.J. and Lee, S.Y. (2021) Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. The World Journal of Men’s Health, 39, 208-221. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Ng, M., Fleming, T., Robinson, M., et al. (2014) Global, Regional, and National Prevalence of Overweight and Obesity in Children and Adults during 1980-2013: A Systematic Analysis for the Global Burden of Disease Study 2013. The Lancet, 384, 766-781. [Google Scholar] [CrossRef]
|
|
[3]
|
Afshin, A., Forouzanfar, M.H., Reitsma, M.B., et al. (2017) Health Effects of Overweight and Obesity in 195 Countries over 25 Years. The New England Journal of Medicine, 377, 13-27. [Google Scholar] [CrossRef]
|
|
[4]
|
Lauby-Secretan, B., Scoccianti, C., Loomis, D., et al. (2016) Body Fatness and Cancer—Viewpoint of the IARC Working Group. The New England Journal of Medicine, 375, 794-798. [Google Scholar] [CrossRef]
|
|
[5]
|
Efsa Panel on Dietetic Products N, Allergies (2011) Scien-tific Opinion on the Substantiation of Health Claims Related to Chitosan and Reduction in Body Weight (ID 679, 1499), Maintenance of Normal Blood LDL-Cholesterol Concentrations (ID 4663), Reduction of Intestinal Transit Time (ID 4664) and Reduction of Inflammation (ID 1985) Pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal, 9, 2214. [Google Scholar] [CrossRef]
|
|
[6]
|
Mesa Ospina, N., Ospina Alvarez, S.P., Escobar Sierra, D.M., et al. (2015) Isolation of Chitosan from Ganoderma lucidum Mushroom for Biomedical Applications. Journal of Materials Science: Materials in Medicine, 26, 135. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Walsh, A.M., Sweeney, T., Bahar, B., et al. (2013) Mul-ti-Functional Roles of Chitosan as a Potential Protective Agent against Obesity. PLoS ONE, 8, e53828. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Moraru, C., Mincea, M.M., Frandes, M., et al. (2018) A Me-ta-Analysis on Randomised Controlled Clinical Trials Evaluating the Effect of the Dietary Supplement Chitosan on Weight Loss, Lipid Parameters and Blood Pressure. Medicina (Kaunas), 54, 109. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Ganesan, K. and Xu, B. (2017) Polyphenol-Rich Dry Common Beans (Phaseolus vulgaris L.) and Their Health Benefits. International Journal of Molecular Sciences, 18, 2331. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Udani, J., Tan, O. and Molina, J. (2018) Systematic Review and Me-ta-Analysis of a Proprietary Alpha-Amylase Inhibitor from White Bean (Phaseolus vulgaris L.) on Weight and Fat Loss in Humans. Foods, 7, 63. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Maccioni, P., Colombo, G., Riva, A., et al. (2010) Reducing Effect of a Phaseolus vulgaris Dry Extract on Operant Self-Administration of a Chocolate-Flavoured Beverage in Rats. British Journal of Nutrition, 104, 624-628. [Google Scholar] [CrossRef]
|
|
[12]
|
Velickovic, K., Wayne, D., Leija, H.A.L., et al. (2019) Caffeine Exposure Induces Browning Features in Adipose Tissue in Vitro and in Vivo. Scientific Reports, 9, Article No. 9104. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Naveed, M., Hejazi, V., Abbas, M., et al. (2018) Chlorogenic Acid (CGA): A Pharmacological Review and Call for Further Research. Biomedicine & Pharmacotherapy, 97, 67-74. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Stefanello, N., Spanevello, R.M., Passamonti, S., et al. (2019) Coffee, Caffeine, Chlorogenic Acid, and the Purinergic System. Food and Chemical Toxicology, 123, 298-313. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Wang, Z., Lam, K.L., Hu, J., et al. (2019) Chlorogenic Acid Allevi-ates Obesity and Modulates Gut Microbiota in High-Fat-Fed Mice. Food Science & Nutrition, 7, 579-588. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Thom, E. (2007) The Effect of Chlorogenic Acid Enriched Coffee on Glucose Absorption in Healthy Volunteers and Its Effect on Body Mass When Used Long-Term in Overweight and Obese People. Journal of International Medical Research, 35, 900-908. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Haidari, F., Samadi, M., Mohammadshahi, M., et al. (2017) Energy Restriction Combined with Green Coffee Bean Extract Affects Serum Adipocytokines and the Body Composition in Obese Women. Asia Pacific Journal of Clinical Nutrition, 26, 1048-1054.
|
|
[18]
|
Flanagan, J., Bily, A., Rolland, Y., et al. (2014) Lipolytic Activity of Svetol®, a Decaffeinated Green Coffee Bean Extract. Phytotherapy Research, 28, 946-948. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Liu, G., Huang, Y., Reis, F.S., et al. (2019) Impact of Nutritional and Environmental Factors on Inflammation, Oxidative Stress, and the Microbiome 2019. BioMed Research International, 2019, Article ID: 5716241. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Yang, C.S. and Hong, J. (2013) Prevention of Chronic Diseases by Tea: Possible Mechanisms and Human Relevance. Annual Review of Nutrition, 33, 161-181. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Glisan, S.L., Grove, K.A., Yennawar, N.H., et al. (2017) Inhibition of Pancreatic Lipase by Black Tea Theaflavins: Comparative Enzymology and in Silico Modeling Studies. Food Chemistry, 216, 296-300. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Wolfram, S., Raederstorff, D., Wang, Y., et al. (2005) TEAVIGO (Epigallocatechin Gallate) Supplementation Prevents Obesity in Rodents by Reducing Adipose Tissue Mass. Annals of Nutrition and Metabolism, 49, 54-63. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Wu, C.H., Lu, F.H., Chang, C.S., et al. (2003) Relationship among Habit-ual Tea Consumption, Percent Body Fat, and Body Fat Distribution. Obesity Research, 11, 1088-1095. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Chen, I.J., Liu, C.Y., Chiu, J.P., et al. (2016) Therapeutic Effect of High-Dose Green Tea Extract on Weight Reduction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Clinical Nutrition, 35, 592-599. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Orlistat, M. (2012) LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda.
|
|
[26]
|
Beyea, M.M., Garg, A.X. and Weir, M.A. (2012) Does Orlistat Cause Acute Kidney Injury? Therapeutic Advances in Drug Safety, 3, 53-57. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Panda, S.R., Jain, M., Jain, S., et al. (2018) Ef-fect of Orlistat versus Metformin in Various Aspects of Polycystic Ovarian Syndrome: A Systematic Review of Ran-domized Control Trials. The Journal of Obstetrics and Gynecology of India, 68, 336-343. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Apovian, C.M., Aronne, L., Rubino, D., et al. (2013) A Random-ized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-Related Risk Factors (COR-II). Obesity (Silver Spring), 21, 935-943. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Fujioka, K. and Braverman-Panza, J. (2016) Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. The Journal of Family Practice, 65, S16-S23.
|
|
[30]
|
Hollander, P., Gupta, A.K., Plodkowski, R., et al. (2013) Effects of Naltrexone Sus-tained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Over-weight and Obese Patients with Type 2 Diabetes. Diabetes Care, 36, 4022-4029. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Melnikova, I. and Wages, D. (2006) Anti-Obesity Therapies. Nature Re-views Drug Discovery, 5, 369-370. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Toplak, H., Hamann, A., Moore, R., et al. (2007) Efficacy and Safety of To-piramate in Combination with Metformin in the Treatment of Obese Subjects with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study. International Journal of Obesity (London), 31, 138-146. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Allison, D.B., Gadde, K.M., Garvey, W.T., et al. (2012) Con-trolled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP). Obesity (Silver Spring), 20, 330-342. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Gadde, K.M., Allison, D.B., Ryan, D.H., et al. (2011) Effects of Low-Dose, Controlled-Release, Phentermine plus Topiramate Combination on Weight and Associated Comorbidities in Overweight and Obese Adults (CONQUER): A Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet, 377, 1341-1352. [Google Scholar] [CrossRef]
|
|
[35]
|
Garvey, W.T., Ryan, D.H., Look, M., et al. (2012) Two-Year Sustained Weight Loss and Metabolic Benefits with Controlled-Release Phentermine/Topiramate in Obese and Overweight Adults (SEQUEL): A Randomized, Placebo-Controlled, Phase 3 Extension Study. The American Journal of Clinical Nutrition, 95, 297-308. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. (2016) Li-raglutide and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 375, 311-322. [Google Scholar] [CrossRef]
|
|
[37]
|
Müller, T.D., Finan, B., Bloom, S.R., et al. (2019) Glucagon-Like Peptide 1 (GLP-1). Molecular Metabolism, 30, 72-130. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
O’neil, P.M., Birkenfeld, A.L., Mcgowan, B., et al. (2018) Efficacy and Safety of Semaglutide Compared with Liraglutide and Placebo for Weight Loss in Patients with Obesity: A Randomised, Double-Blind, Placebo and Active Controlled, Dose-Ranging, Phase 2 Trial. The Lancet, 392, 637-649. [Google Scholar] [CrossRef]
|
|
[39]
|
Kadouh, H., Chedid, V., Halawi, H., et al. (2020) GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity. The Journal of Clinical Endocrinology & Metabolism, 105, 1552-1563. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015) A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. The New England Journal of Medicine, 373, 11-22. [Google Scholar] [CrossRef]
|
|
[41]
|
Hurren, K.M. and Berlie, H.D. (2011) Lorcaserin: An Investigation-al Serotonin 2C Agonist for Weight Loss. American Journal of Health-System Pharmacy, 68, 2029-2037. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Shukla, A.P., Kumar, R.B. and Aronne, L.J. (2015) Lorcaserin HCL for the Treatment of Obesity. Expert Opinion on Pharmacotherapy, 16, 2531-2538. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Lorcaserin, M. (2012) LiverTox: Clinical and Research In-formation on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethes-da.
|
|
[44]
|
Sharretts, J., Galescu, O. and Gomatam, S., et al. (2020) Cancer Risk Associated with Lorcaserin—The FDA’s Review of the CAMELLIA-TIMI 61 Trial. The New England Journal of Medicine, 383, 1000-1002. [Google Scholar] [CrossRef]
|